Evidence map›Paper›PMID 28226181›Full record

ArticleDiabetic medicine : a journal of the British Diabetic Association2017

Use of self-collected capillary blood samples for islet autoantibody screening in relatives: a feasibility and acceptability study.

Y Liu, L E Rafkin, D Matheson, C Henderson, D Boulware, R E J Besser, C Ferrara, L Yu, A K Steck, P J Bingley and 1 more

Registry-linked trialOpen access · greenAbstract readEvaluation Study
In one paragraph

Article in Diabetic medicine : a journal of the British Diabetic Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06815081 (A Study to Determine a Capillary Alternative to the Gold Standard Oral Glucose Tolerance Test), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06815081 recruitingnot on this mapstarted 2024, after this paper: background citation

A Study to Determine a Capillary Alternative to the Gold Standard Oral Glucose Tolerance Test

TypeobservationalSponsorUniversity of OxfordRan2024 to 2027Enrolled135ConditionsType 1 Diabetes (T1D), Type 2 Diabetes
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Impact of screening programmes for type 1 diabetes in youth: A systematic review and meta-analysis.Diabetic medicine : a journal of the British Diabetic Association · 2026
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The relationship between GAD65 autoantibody and the risk of T1DM onset.Journal of diabetes and metabolic disorders · 2022
    Review
  17. Article
  18. Review
  19. Birth and coming of age of islet autoantibodies.Clinical and experimental immunology · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Y LiuDivision of Diabetes and Nutritional Sciences, King's College London, London, UK.ORCID 0000-0002-8518-8756
L E RafkinUniversity of Miami Miller School of Medicine, Miami.
D MathesonUniversity of Miami Miller School of Medicine, Miami.
C HendersonUniversity of South Florida Health Informatics Institute, Tampa, FL, USA.
D BoulwareUniversity of South Florida Health Informatics Institute, Tampa, FL, USA.
R E J BesserDepartment of Paediatrics, University of Oxford, Oxford, UK.
C FerraraDivision of Pediatric Endocrinology and Diabetes, University of California, San Francisco, CA.
L YuBarbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, USA.
A K SteckBarbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, USA.
P J BingleySchool of Clinical Sciences, University of Bristol, Bristol, UK.
Type 1 Diabetes TrialNet Study Group
University of Miami · USUniversity of South Florida · USKing's College London · GBUniversity of Bristol · GBUniversity of California, San Francisco · USUniversity of Oxford · GB

Funding

Northwest Clinical Center for Type 1 Diabetes - TrialNetU01DK061034 · NIDDK · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI GREENBAUM, CARLA J · 2001 to 2018
$10.3M
Type I Diabetes Trialnet at StsnfordU01DK061042 · NIDDK · STANFORD UNIVERSITY · PI WILSON, DARRELL M · 2001 to 2018
$8.5M
UCSF Trialnet: A Phase II Trial of Imatimib in New Onset Type I DiabetesU01DK061010 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GITELMAN, STEPHEN E · 2001 to 2018
$8.1M
Type 1 Diabetes-A Proposal for Prevention & InterventionU01DK085476 · NIDDK · UNIVERSITY OF MINNESOTA · PI MORAN, ANTOINETTE M. · 2009 to 2018
$7.1M
Prediction and Prevention of Type I DiabetesU01DK061058 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BECKER, DOROTHY J · 2001 to 2018
$6.5M
TrialNet: University of Florida Clinical Center and NetworkU01DK085461 · NIDDK · UNIVERSITY OF FLORIDA · PI HALLER, MICHAEL JAMES · 2009 to 2018
$5.9M
TrialNet: Diabetes Type 1 PreventionU01DK085509 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI GOTTLIEB, PETER A · 2009 to 2018
$5.8M
Type 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1DU01DK085499 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BAIDAL, DAVID · 2009 to 2018
$4.9M
Vanderbilt University: Clinical Center Application, Type 1 Diabetes TrialNetU01DK085465 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RUSSELL, WILLIAM E · 2009 to 2018
$4.8M
Type 1 Diabetes TrialNet: Clinical Center at Yale University (U01)U01DK085466 · NIDDK · YALE UNIVERSITY · PI HEROLD, KEVAN C · 2009 to 2018
$3.3M
Type 1 Diabetes TrialNet at Indiana University Clinical CenterU01DK085505 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI DIMEGLIO, LINDA A · 2009 to 2013
$3.0M
Type 1 Diabetes TrialNet: Clinical Centers (U01)U01DK085453 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI RASKIN, PHILIP · 2009 to 2013
$3.0M
NIDDK NIH HHS U01 DK061010NIDDK NIH HHS U01 DK061034NIDDK NIH HHS U01 DK061042NIDDK NIH HHS U01 DK061058NIDDK NIH HHS U01 DK085453NIDDK NIH HHS U01 DK085461NIDDK NIH HHS U01 DK085463NIDDK NIH HHS U01 DK085465NIDDK NIH HHS U01 DK085466NIDDK NIH HHS U01 DK085476NIDDK NIH HHS U01 DK085499NIDDK NIH HHS U01 DK085504NIDDK NIH HHS U01 DK085505NIDDK NIH HHS U01 DK085509NIDDK NIH HHS U01 DK103153NIDDK NIH HHS U01 DK103180NIDDK NIH HHS U01 DK103266NIDDK NIH HHS U01 DK107013NIDDK NIH HHS U01 DK107014
6 · The paper itself

Abstract

aimsTo evaluate the feasibility of using self-collected capillary blood samples for islet autoantibody testing to identify risk in relatives of people with Type 1 diabetes.

methodsParticipants were recruited via the observational TrialNet Pathway to Prevention study, which screens and monitors relatives of people with Type 1 diabetes for islet autoantibodies. Relatives were sent kits for capillary blood collection, with written instructions, an online instructional video link and a questionnaire. Sera from capillary blood samples were tested for autoantibodies to glutamic acid decarboxylase, islet antigen-2, insulin and zinc transporter 8. 'Successful' sample collection was defined as obtaining sufficient volume and quality to provide definitive autoantibody results, including confirmation of positive results by repeat assay.

resultsIn 240 relatives who returned samples, the median (range) age was 15.5 (1-49) years and 51% were male. Of these samples, 98% were sufficient for glutamic acid decarboxylase, islet antigen-2 and zinc transporter 8 autoantibody testing and 84% for insulin autoantibody testing and complete autoantibody screen. The upper 90% confidence bound for unsuccessful collection was 4.4% for glutamic acid decarboxylase, islet antigen-2 and/or zinc transporter 8 autoantibody assays, and 19.3% for insulin autoantibodies. Despite 43% of 220 questionnaire respondents finding capillary blood collection uncomfortable or painful, 82% preferred home self-collection of capillary blood samples compared with outpatient venepuncture (90% of those aged <8 years, 83% of those aged 9-18 years and 73% of those aged >18 years). The perceived difficulty of collecting capillary blood samples did not affect success rate.

conclusionsSelf-collected capillary blood sampling offers a feasible alternative to venous sampling, with the potential to facilitate autoantibody screening for Type 1 diabetes risk.

Indexed as

Family HealthSelf CareAdolescentAdultAsymptomatic DiseasesAutoantibodiesAutoimmune DiseasesBlood Specimen CollectionCapillariesChildDiabetes Mellitus, Type 1Early DiagnosisFeasibility StudiesFemaleHumansIslets of LangerhansAutoantibodies

Identifiers

PMID28226181
PMCPMC5816681
OpenAlexW2589989165

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.